Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. - Wikidata - wikimedia - TriplyDB

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

http://www.wikidata.org/entity/Q33276349

about

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats Advances in recombinant antibody manufacturing Fc glycans of therapeutic antibodies as critical quality attributes Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.A novel mechanism for LSECtin binding to Ebola virus surface glycoprotein through truncated glycans.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy High throughput quantification of N-glycans using one-pot sialic acid modification and matrix assisted laser desorption ionization time-of-flight mass spectrometry Alterations in glycopeptides associated with herceptin treatment of human breast carcinoma mcf-7 and T-lymphoblastoid cells Glycosylation profiling of therapeutic antibodies in serum samples using a microfluidic CD platform and MALDI-MS.Analysis and validation of carbohydrate three-dimensional structures.Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk Comparative study of idursulfase beta and idursulfase in vitro and in vivo.Designing polymers with sugar-based advantages for bioactive delivery applications Increased serum clearance of oligomannose species present on a human IgG1 molecule.Antibody therapeutics: isotype and glycoform selection.Mammalian glycosylation in immunity.Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-α/Fc fusion proteins expressed in Pichia pastoris.Stability of IgG isotypes in serum.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.Glycosylation: impact, control and improvement during therapeutic protein production.Assessment of the metabolism of therapeutic proteins and antibodies.Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Glycosylation of monoclonal antibody products: Current status and future prospects.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Fed-batch CHO cell t-PA production and feed glutamine replacement to reduce ammonia production.High-Throughput Analysis of IgG Fc Glycopeptides by LC-MS.Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.Pharmacokinetics of Monoclonal Antibodies.Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.The effect of Fc glycan forms on human IgG2 antibody clearance in humans.Identification of manipulated variables for a glycosylation control strategy.Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation profiles.

P2860

Q24619854-A6B4192A-8B3A-45E0-999F-5F8C3CC0102F Q26764949-49719DA4-6A2F-4270-90B1-B0D65D2A8149 Q26799266-6B954C31-2081-4543-BAC6-6BCE4D26D712 Q28652788-F1A34894-9CEE-4BA6-9AE5-56540A3305BB Q31004131-9C2C2A84-20B2-4728-883A-FAFA4B356CD0 Q33305051-4F1B9CF5-1E4B-44E1-BEB9-41EE2D455F2D Q33437488-1D4A1CF6-AEA1-41A2-B5E3-43939A099AEE Q33586660-17408919-0B5A-43E4-A89B-3F00101689EA Q33619621-60490961-1812-4DCA-B967-F881575B475E Q33910762-96FDCDDC-9A75-4E67-9E37-99B6A0A1416A Q34697409-6AC30C6D-67B9-4C09-BDD0-CD732075BE8A Q34930770-BC1FA68E-9D0C-41A4-9C03-3C2DCDF40D99 Q35129041-C8FDF1AA-7A73-4B6C-B82C-42FF74B14150 Q35835707-9421122C-A0CA-4544-80A0-B12B007DC673 Q36188048-8C9D4272-872B-44E8-8379-FBFA8F56F6D3 Q36307576-F2DA9101-3AE3-421C-B167-87FA635C7214 Q36402812-303813E9-655A-4685-8105-BEDFDC75A700 Q36922260-CCCA0556-6C45-4AAB-9BE8-D3B6AEC7D91E Q37290930-52F639D3-438E-4E0C-B080-72E06C766504 Q37481254-8535AB73-CE49-4111-8C11-E49C1851F3D5 Q37734089-2C178094-7C28-4E7E-854D-D98AB5DBDC8A Q37999739-2725270C-FE42-4333-8C97-51D43E013A2E Q38028654-23119052-BAE5-4039-81ED-9B672247306F Q38065955-BBEF4FB3-B59D-41D1-81E6-555321E5C300 Q38115691-CC189315-3355-4CA3-BEFC-9F2210A9C372 Q38126913-5660DB69-A0B7-4D99-825C-A50CFD7F2082 Q38217623-7AE32691-132C-4922-AC88-3F982297367A Q38408253-2DD077CE-984F-46A5-BD12-5DD09D2C3216 Q38489049-CB8C4FCC-9BCA-4D0B-A416-BFD6307C54EB Q38807919-4D63160B-F22C-43DD-9248-C878CCDC1E17 Q38831148-6BBA3AF5-2D00-4267-9EA7-9B8CA1388D88 Q39249582-8FE7C248-F92E-479A-B2D2-6B0F53DBD64F Q39289177-6D9C4BAE-0233-4F1C-A874-16AD45E7E6A8 Q41140868-75E7C632-E34E-407F-83C3-A6837093C23B Q42118646-6145C75F-ED56-4C18-B08F-F3630DA47606 Q42415905-77177BCC-94A9-45FC-AC87-1571B5F1DAFB Q44852748-40AB470D-4FA7-48D3-83E4-018CA639962E Q46272691-D01A37AA-E093-4BF7-97CE-58C690FB3DE1 Q46978895-8668A4BB-E85D-4B44-ACA5-BF895F079E48 Q47598608-39498A07-B2A8-40EC-AA27-EC516EF98AE1

P2860

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.

http://www.wikidata.org/entity/Q33276349

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@ast

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@en

type

label

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@ast

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@en

prefLabel

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@ast

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@en

P1433

Q33276349-61249A53-7CA8-498A-BC51-9429D4658201

P1476

Q33276349-D61AB1CD-7CAD-4774-9243-8066A320186E

P2093

Q33276349-1CDAEAD3-2624-4307-8B92-F4CEC3D61514

Q33276349-4106DDB0-B2A3-4216-8536-697CE5ADDB7E

Q33276349-6D822D79-8BD8-466A-94FB-7868575BB50B

Q33276349-8875BA07-0950-4AB3-923B-8C67A3B0AAC8

Q33276349-A02FD39A-B040-49C2-8827-252BA90B76C9

Q33276349-A0D8AC29-673B-4996-9E9D-4FB9543380F4

Q33276349-B3168B75-B6FA-4EFE-B878-12419446D4A1

Q33276349-CB5F2DED-C75C-469A-8AD6-A88FC552CC9E

P2860

Q33276349-018CEFCD-006C-4DAC-BDC0-52D4E5114A3F

Q33276349-0C2D766D-8681-44CD-98AB-3A62A86D3FC2

Q33276349-1E4E8294-CE35-4AF1-AAA1-6C583B85CC6B

Q33276349-26D367A2-F720-4B79-BD7A-3A0EA08CAF79

Q33276349-325A785E-204F-4F49-BF4C-85C72A9DBC0A

Q33276349-36A68B35-46D8-4527-915E-A3663298C882

Q33276349-3E6D9F5A-2534-462A-8E5F-B8A3D01DEE99

Q33276349-4022A891-CCB1-46AD-8A26-EF21130370D5

Q33276349-499010A4-0DFB-4796-B848-C372AC0B90E8

Q33276349-6B3DE2E1-B8C0-4528-9447-97B522DCF539

P304

Q33276349-CD7E91B5-C86B-4FB7-885C-356DBBEAA45B

P31

Q33276349-389CCB1B-7CA8-4B60-A9CE-8561FA78F3DC

P356

Q33276349-128BDB2F-F591-41A9-9812-0AB45676A653

P433

Q33276349-CD88B8A0-F0E7-4E1A-AF5A-B45F5DA30BCB

P478

Q33276349-AAA9C156-53F5-4E65-A05C-4C36A5E5E7D7

P577

Q33276349-5DDF6FB0-E2CD-4156-9E03-22F11DAF2F3F

P698

Q33276349-1DBC4C83-5239-4A37-A393-C87A803AE67A

P356

P1433

P1476

Selective clearance of glycofo ...... humans and cynomolgus monkeys.

@en

P2093

Andrew J S Jones

http://www.w3.org/2001/XMLSchema#string

Damon I Papac

http://www.w3.org/2001/XMLSchema#string

Edward H Chin

http://www.w3.org/2001/XMLSchema#string

Johannes Kneer

http://www.w3.org/2001/XMLSchema#string

John E Battersby

http://www.w3.org/2001/XMLSchema#string

Rodney Keck

http://www.w3.org/2001/XMLSchema#string

Sharon A Baughman

http://www.w3.org/2001/XMLSchema#string

Yvonne S Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation

The mannose receptor is a pattern recognition receptor involved in host defense

Fc receptors and their interactions with immunoglobulins

A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis.

Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages.

The mannose receptor and other macrophage lectins.

Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.

Clearing up glycoprotein hormones.

Analysis of acidic oligosaccharides and glycopeptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Glycosylation of recombinant protein therapeutics: control and functional implications.

P304

529-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/GLYCOB/CWM017

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17331977

http://www.w3.org/2001/XMLSchema#string